Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Weight Loss Maintenance
NCT05885074Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Empagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: Change in Resting Energy Expenditure at 12 months. Planned start Jan 2025; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05885074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885074.